Published Date: 13 Mar 2023
The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.
Read Full NewsSusan Corbridge, PhD, and Alanna Kavannagh, MSN, CCRN, discuss the role of advanced practice providers on the evolving pulmonary and critical care teams during CHEST 2025.
The phase 3 study aims to confirm findings from the HEALEY ALS platform trial in patients with early-stage rapidly progressive ALS, which suggested potential benefits of pridopidine across multiple domains.
Holzem spoke in this interview about several additional highlights from her session at SDPA Fall regarding red flags in dermatology and when to admit from the clinic.
Key Skin Cancer Terms Not Understood by Almost 1/3 of Patients Surveyed
1.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
2.
Year in Review: Multiple Myeloma
3.
Study finds 81% of cancer cures touted by TikTok videos are fake
4.
How artificial intelligence could significantly improve the prognosis for cancer patients.
5.
Sports for girls are frequently abandoned due to uniform issues.
1.
Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia
2.
Innovative Strategies in Prostate Cancer Management: From Surveillance to Systemic Therapies
3.
Unmasking the Subtle Symptoms of Colon Cancer
4.
Lymphomatoid Papulosis: What You Need to Know
5.
Chondroma: What it is and How it Affects Your Health
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation